What was recalled
This page synthesizes the mycoprotein framework around commercial pet food alternative protein development. Mycoprotein is protein produced from Fusarium venenatum filamentous fungi grown through industrial fermentation, using glucose, wheat-derived starch, or other carbohydrate substrates. The fungal biomass is harvested through filtration, heat-treated to reduce RNA content (typical post-harvest RNA reduction targets 2% or less on dry-matter basis to manage uric acid considerations), and processed into texturized protein products through extrusion or alternative texturizing methods. The fungal hyphae structure produces meat-like texture characteristics that make mycoprotein particularly suitable for meat-analog applications in human food.
The commercial heritage centers on the Quorn brand, launched in 1985 by Marlow Foods (originally a joint venture between Rank Hovis McDougall and Imperial Chemical Industries, now owned by Monde Nissin Corporation). Quorn was the first commercial mycoprotein product, developed through 1960s-1980s industrial research at Rank Hovis McDougall's Marlow facility. The product launched in UK retail in 1985 and expanded across 17+ countries over the subsequent 40 years. UK regulatory framework approved mycoprotein for human food in 1984, with subsequent EU and other national regulatory approvals following. US FDA recognized mycoprotein as GRAS in 2002 with subsequent expanded use approvals. Quorn maintains commercial dominance with over $700M annual revenue as of 2024.
The nutritional profile of mycoprotein supports pet food applications. Protein content typically 50% on dry-matter basis with complete amino acid profile including all essential amino acids in adequate proportions for both canine and feline AAFCO requirements. Dietary fiber content is approximately 25% on dry-matter basis, derived from fungal cell wall components — beta-glucan polysaccharide (similar to oat beta-glucan with established cholesterol-lowering and immunomodulatory effects in human nutrition) and chitin polysaccharide (similar to insect-source chitin with potential prebiotic effect). The combined high-protein high-fiber profile is distinctive among alternative proteins and produces formulation implications for pet food applications — the fiber content provides functional benefits but reduces effective protein density in finished pet food formulations. Low saturated fat (<1% dry matter), trace cholesterol, substantial B-vitamin content from fungal biomass (particularly B12 if appropriately supplemented; some B-vitamin content is naturally present in fungal biomass).
Why it was recalled
The structural concerns have three layers. Layer one — US AAFCO definition framework lags UK and EU regulatory pathways: mycoprotein has 40+ year UK regulatory approval and US FDA GRAS recognition (2002) for human food, but AAFCO has not yet defined mycoprotein specifically for commercial US pet food. Pet food brands using mycoprotein operate through alternative regulatory pathways including FDA GRAS self-affirmation cross-reference, FDA-CVM no-questions-letters, and state-level regulatory frameworks. The pathway uncertainty is similar to other alternative protein categories (cricket, mealworm, precision fermentation) but mycoprotein has stronger established human food heritage that may shorten US pet food regulatory framework development.
Layer two — allergenicity profile requires consideration: mycoprotein has documented allergenicity in some human consumers with mold and fungal allergens. Cross-reactivity with mold-allergen sensitivity has been characterized in human food contexts. Companion animal mycoprotein allergy is reported but with limited prevalence data. Pets with established mold-allergy or fungal-sensitivity history should approach mycoprotein-containing pet food with caution and veterinary consultation. The framework intersects with broader fungal-protein allergenicity considerations and with Aspergillus oryzae Koji-fermentation protein covered separately on our microbial single-cell protein page.
Layer three — high fiber content creates formulation considerations: the distinctive ~25% dietary fiber content from fungal cell walls produces formulation implications beyond simpler protein-source substitution. Pet food formulations incorporating mycoprotein need to account for the elevated fiber contribution in overall macronutrient balance and digestibility considerations. Some formulations defat or de-fiber mycoprotein to produce higher-protein lower-fiber concentrate; others use whole mycoprotein for dual-purpose protein-and-fiber contribution. The formulation framework requires engineering specific to mycoprotein characteristics, and pet food brands using mycoprotein typically address this through formulation design transparency at brand customer service tier.
Health risks for your pet
Mycoprotein produced through standard industrial fermentation and processing operations meets food safety requirements equivalent to other regulated food ingredients in jurisdictions where it is approved. The nutritional adequacy supports pet food applications with complete amino acid profile and substantial fiber content with established functional benefits. Theoretical health-impact concerns include: (i) fungal allergenicity — mycoprotein has documented allergenicity in some human consumers with mold and fungal allergens; pets with mold-allergy or fungal-sensitivity history should approach with caution; (ii) high RNA content of raw fungal biomass — raw Fusarium venenatum biomass contains 9-12% RNA on dry-matter basis, with post-harvest RNA reduction processing targeting 2% or less to manage uric acid considerations; pet food brands using mycoprotein should specify RNA reduction processing in regulatory and consumer-disclosure documentation; (iii) high fiber content gastrointestinal effects — the ~25% fiber content can produce gastrointestinal changes during transition (increased stool volume, transient softer stool, gas) that typically resolve over 1-2 weeks; (iv) mycotoxin contamination potential — commercial mycoprotein production uses controlled fermentation conditions with mycotoxin testing in finished product; reputable mycoprotein producers maintain testing protocols; (v) long-term companion animal feeding evidence gap — multi-year cohort companion animal evidence is limited despite substantial human food feeding heritage.
The more substantive concern is regulatory pathway uncertainty for US pet food applications: US pet food brands using mycoprotein operate in a developing regulatory framework leveraging FDA GRAS human food cross-reference and FDA-CVM regulatory engagement rather than fully-defined AAFCO ingredient status. Consumer disclosure around regulatory pathway is typically absent.
What to do if you bought affected product
Pet owners can navigate mycoprotein pet food meaningfully through several practical approaches: (1) recognize mycoprotein's substantial human food heritage — 40+ year UK regulatory approval and US FDA GRAS recognition (2002) provide strong safety precedent that pet food applications can leverage; (2) treat mycoprotein pet food as innovation-tier with strong human food precedent — commercial pet food applications are emerging but the underlying safety framework is well-established through Quorn and other human food applications; (3) check for mold-allergy or fungal-sensitivity history — mycoprotein has documented fungal allergenicity in some human consumers; pets with established mold-allergy or fungal-sensitivity should approach with caution and veterinary consultation; (4) recognize the high fiber content — the ~25% fungal cell wall fiber content provides functional benefits but produces gastrointestinal adjustment during transition; introduce mycoprotein pet food gradually over 1-2 weeks; (5) verify regulatory pathway disclosure from brand customer service — ask which regulatory pathway applies (FDA GRAS cross-reference from human food, FDA-CVM no-questions-letter, AAFCO definition status); (6) recognize the sustainability advantages — mycoprotein offers favorable sustainability profile (substantially lower land and water footprint than livestock agriculture, fast production cycle through industrial fermentation); (7) discuss mycoprotein pet food options with your veterinarian for pets with chronic conditions or specific dietary needs; (8) watch the AAFCO Ingredient Definitions Committee and Pet Food Industry trade press for US pet food regulatory framework development; (9) reference our microbial single-cell protein, yeast biomass protein, and tranche-14 alternative protein pages for related category context.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently include mycoprotein specifically in the database per our published methodology, since commercial US pet food products using these ingredients are limited and AAFCO ingredient definition framework is still developing. Future rubric extension under consideration: as mycoprotein reaches broader US commercial pet food adoption with AAFCO definition or established FDA-CVM regulatory pathway, rubric integration would address nutritional adequacy (complete amino acid profile, fiber functional benefits), sustainability favorability, and developing long-term companion animal feeding evidence. The broader alternative protein and emerging-category framework is covered across our microbial single-cell protein, yeast biomass protein, precision-fermented animal protein, cultured meat, and tranche-14 alternative protein controversy pages. For now, our recommendation: treat mycoprotein pet food as innovation-tier alternative protein with substantial human food heritage and developing US pet food regulatory framework.